Antigingivitis agent-by-agent final formula performance standards suggested by FDA cmte.
This article was originally published in The Rose Sheet
Executive Summary
ANTIGINGIVITIS AGENT-SPECIFIC FINAL FORMULA PERFORMANCE STANDARDS PREFERABLE over the development of performance standards for final formulations by pharmacological class, Max Listgarten, DDS, University of Pennsylvania, said at an Oct. 30 meeting of FDA's Nonprescription Drugs Advisory Committee's Dental Plaque Subcommittee in Gaithersburg, Md. The meeting continued the subcommittee's ongoing effort to propose a framework for an antigingivitis/antiplaque products OTC monograph. One issue discussed by the subcommittee was the development of appropriate performance standards for final formulations of gingivitis products.